A Multi-National, Randomised, Open-Label, Parallel, Phase III Non-Inferiority Study Comparing NK105 and Paclitaxel in Metastatic or Recurrent Breast Cancer Patients

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-019-0391-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Antiviral Therapy
Infectious DiseasesPharmacology
2017English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Urology
Urology
2010English

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Uterotonics in Elective Caesarean Delivery: A Randomised Non-Inferiority Study Comparing Carbetocin 20 Μg and 100 Μg

Anaesthesia
AnesthesiologyPain Medicine
2018English

Eribulin Versus Dacarbazine in Patients With Leiomyosarcoma: Subgroup Analysis From a Phase 3, Open-Label, Randomised Study

British Journal of Cancer
Cancer ResearchOncology
2019English

A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients With Metastatic Esophageal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy